EGFR and breast cancer: Multiple transactivations between GPCRs and EGFR that induce oncogenic pathways are described, such as GPR30 and EGFR, to activate the oncogenic MAPK and PI3K/Akt pathways or the protease-activated receptor 1 and EGFR in breast cancer [141,142].